T. Rowe Price Associates’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

T. Rowe Price Associates’s Portfolio CNST Stock Details CNST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-17,840	Closed	-$603K	–	3037
2021 Q2	$603K	Sell	17,840 -524,199	-97%	-$13.4M	﹤0.01%	2300
2021 Q1	$12.7M	Buy	542,039 +284,777	+111%	+$8.63M	﹤0.01%	1355
2020 Q4	$7.41M	Sell	257,262 -216,071	-46%	-$5.44M	﹤0.01%	1389
2020 Q3	$9.59M	Buy	473,333 +199,294	+73%	+$4.87M	﹤0.01%	1309
2020 Q2	$8.23M	Sell	274,039 -253,828	-48%	-$9.14M	﹤0.01%	1325
2020 Q1	$16.6M	Buy	527,867 +124,292	+31%	+$4.32M	﹤0.01%	1123
2019 Q4	$19M	Buy	403,575 +53,350	+15%	+$1.54M	﹤0.01%	1199
2019 Q3	$2K	Buy	350,225 +32	+0%	+$267	﹤0.01%	2518
2019 Q2	$4K	Buy	+350,193	New	+$3.9M	﹤0.01%	2541

T. Rowe Price Associates's CNST Position: Q3 2021 in Review

T. Rowe Price Associates sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q3 2021, closing a stake of 17,840 shares — an estimated $603K sold.

T. Rowe Price Associates first reported a position in CNST in Q2 2019 and held it in 9 quarters. The position peaked at $19M in Q4 2019. 0 funds tracked by Wall St. Rank hold CNST as of Q3 2021.

T. Rowe Price Associates reported no remaining Constellation Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
T. Rowe Price Associates sold 17,840 Constellation Pharmaceuticals, Inc. shares in Q3 2021, an estimated $603K.
T. Rowe Price Associates first reported a position in Constellation Pharmaceuticals, Inc. in Q2 2019 and held it in 9 quarters.
T. Rowe Price Associates's Constellation Pharmaceuticals, Inc. position peaked at $19M in Q4 2019.
0 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q3 2021.

Based on T. Rowe Price Associates's 13F filing for Q3 2021, filed 15 Nov 2021.